Modality
Vaccine
MOA
TNFi
Target
TIM-3
Pathway
Amyloid
Hemophilia A
Development Pipeline
Preclinical
Jul 2024
→ Oct 2026
PreclinicalCurrent
NCT06942091
2,236 pts·Hemophilia A
2024-07→2026-10·Completed
2,236 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-10-187mo awayInterim· Hemophilia A
Trial Timeline
Q3Q42025Q2Q3Q42026Q2Q3Q4
Preclinical
Complet…
Catalysts
Interim
2026-10-18 · 7mo away
Hemophilia A
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06942091 | Preclinical | Hemophilia A | Completed | 2236 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| AZN-7403 | AstraZeneca | Phase 2/3 | FGFR | |
| TAK-8262 | Takeda | NDA/BLA | Tau | |
| Talalemzoparlimab | Gilead Sciences | Phase 1 | FcRn | |
| REG-6699 | Regeneron | Phase 2/3 | TIM-3 | |
| Ribozanubrutinib | Genmab | Approved | GPRC5D | |
| Nidasacituzumab | United Therapeutics | Phase 1/2 | TIM-3 | |
| 369-789 | Hansoh Pharma | Phase 3 | PI3Kα | |
| Liratinib | Krystal Biotech | NDA/BLA | TIM-3 | |
| Doxazasiran | Axsome | Phase 1 | TIM-3 | |
| Rimanesiran | Merus | Phase 1 | TIM-3 |